Regulatory Developments October 2018

03a_RegNews_Alternate_770x2953.jpg


Notices of rates for FDA biosimilar and prescription drug user fees, a request for input on transition of the National Drug Code, and guidance for industry. 

 

Related Stories

Table of Contents
Regulatory Developments
October/November 2018